Orienza, Vilma C.

HRN: 28-69-41  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/14/2026
CO-AMOXICLAV 625MG (TAB)
03/14/2026
03/20/2026
PO
625mg
Q8
Lacerated Wound
Pending Pharmacy Acceptance 

 Indication:  Prophylaxis    Type of Infection:  Prophylaxis    Compliance to guidelines: